The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key ...